Bmy stock forecast 2025 trade volumes for BMY have steadily

Trade volumes for BMY have steadily risen, backing a technical case where the 2025 stock forecast favors breakout potential above the $70 resistance zone. The biopharmaceutical company's shares have seen a decrease of 16.53% over the last month, not keeping up with the Medical sector's loss of 7.47% and the S&P 500's loss of 4.17%. This configuration is notably more bullish than two months ago when the stock had a consensus “Hold” rating, and only six analysts gave “Strong Buy” ratings. The healthcare equity landscape suggests BMY stock forecast 2025 will track upward momentum if FDA clearance for its hematology assets arrives within Q2–Q3 timelines.